Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation.
Kelly RM, Goren EM, Taylor PA, Mueller SN, Stefanski HE, Osborn MJ, Scott HS, Komarova EA, Gudkov AV, Holländer GA, Blazar BR. Kelly RM, et al. Among authors: scott hs. Blood. 2010 Feb 4;115(5):1088-97. doi: 10.1182/blood-2009-05-223198. Epub 2009 Dec 4. Blood. 2010. PMID: 19965631 Free PMC article.
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
Saygin C, Roloff G, Hahn CN, Chhetri R, Gill S, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop M, Kosuri S, Das S, Singhal D, Venugopal P, Homan CC, Brown A, Scott HS, Hiwase D, Godley LA. Saygin C, et al. Among authors: scott hs. Blood Adv. 2023 Feb 28;7(4):549-554. doi: 10.1182/bloodadvances.2022008172. Blood Adv. 2023. PMID: 36001442 Free PMC article.
Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.
Wechalekar MD, Zhao LP, Kutyna MM, Hong LE, Li J, Hung K, Scott HS, Brown A, Hahn CC, Kassahn K, Ladon D, Yeung DT, Thomas D, Patnaik M, Proudman S, Ades L, Shah MV, Kok CH, Hiwase DK. Wechalekar MD, et al. Among authors: scott hs. Blood Cancer J. 2024 Jul 19;14(1):116. doi: 10.1038/s41408-024-01093-9. Blood Cancer J. 2024. PMID: 39030163 Free PMC article. No abstract available.
Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen.
Alimohammadi M, Björklund P, Hallgren A, Pöntynen N, Szinnai G, Shikama N, Keller MP, Ekwall O, Kinkel SA, Husebye ES, Gustafsson J, Rorsman F, Peltonen L, Betterle C, Perheentupa J, Akerström G, Westin G, Scott HS, Holländer GA, Kämpe O. Alimohammadi M, et al. Among authors: scott hs. N Engl J Med. 2008 Mar 6;358(10):1018-28. doi: 10.1056/NEJMoa0706487. N Engl J Med. 2008. PMID: 18322283 Free article.
Hematopoietic defects in the Ts1Cje mouse model of Down syndrome.
Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, Hewitt CA, Scott HS. Carmichael CL, et al. Among authors: scott hs. Blood. 2009 Feb 26;113(9):1929-37. doi: 10.1182/blood-2008-06-161422. Epub 2008 Dec 24. Blood. 2009. PMID: 19109561 Free article.
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.
Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong CE, Schreiber AW, Feng J, Phillips K, Wang PPS, Ha T, Homan CC, King-Smith SL, Rawlings L, Vakulin C, Dubowsky A, Burdett J, Moore S, McKavanagh G, Henry D, Wells A, Mercorella B, Nicola M, Suttle J, Wilkins E, Li XC, Michaud J, Brautigan P, Cannon P, Altree M, Jaensch L, Fine M, Butcher C, D'Andrea RJ, Lewis ID, Hiwase DK, Papaemmanuil E, Horwitz MS, Natsoulis G, Rienhoff HY, Patton N, Mapp S, Susman R, Morgan S, Cooney J, Currie M, Popat U, Bochtler T, Izraeli S, Bradstock K, Godley LA, Krämer A, Fröhling S, Wei AH, Forsyth C, Mar Fan H, Poplawski NK, Hahn CN, Scott HS. Brown AL, et al. Among authors: scott hs. Blood Adv. 2020 Mar 24;4(6):1131-1144. doi: 10.1182/bloodadvances.2019000901. Blood Adv. 2020. PMID: 32208489 Free PMC article.
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK. Shah MV, et al. Among authors: scott hs. Blood Cancer J. 2023 Apr 11;13(1):51. doi: 10.1038/s41408-023-00821-x. Blood Cancer J. 2023. PMID: 37041128 Free PMC article.
291 results